Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Shareholders' Equity (Unaudited)

v3.22.1
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total stockholders’ equity   $ 8 $ 414,819 $ (58,783)
Balance, beginning of period at Dec. 31, 2020   8 414,819 (58,783)
Fair value of private warrants converted to public warrants     13,922  
Costs related to warrants     0  
Stock-based compensation expense     6,665  
Stock issued under stock compensation plan     1,191  
Issuance of common stock, net of issuance costs   1 (815)  
Net income (loss) $ (94,734)     (94,734)
Balance, end of period at Mar. 31, 2021 282,274 9 435,782 (153,517)
Total stockholders’ equity 282,274 9 435,782 (153,517)
Total stockholders’ equity 500,265 10 619,145 (118,890)
Balance, beginning of period at Dec. 31, 2021 500,265 10 619,145 (118,890)
Fair value of private warrants converted to public warrants     0  
Costs related to warrants     (55)  
Stock-based compensation expense     13,750  
Stock issued under stock compensation plan     373  
Issuance of common stock, net of issuance costs   0 0  
Net income (loss) (26,386)     (26,386)
Balance, end of period at Mar. 31, 2022 487,947 10 633,213 (145,276)
Total stockholders’ equity $ 487,947 $ 10 $ 633,213 $ (145,276)